Welcome to LookChem.com Sign In|Join Free

CAS

  • or

299-42-3

Post Buying Request

299-42-3 Suppliers

Recommended suppliersmore

This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.

299-42-3 Usage

Chemical Properties

white crystals or powder

Originator

CAM,Rybar-UK

Uses

Different sources of media describe the Uses of 299-42-3 differently. You can refer to the following data:
1. Ephedrine, 1-phenyl-2-methylaminopropanol, C6H5 CH(OH)CH(NHCH3)CH3, is a white-to-colorless granular substance, unctuous (greasy) to the touch, and hygroscopic. The compound gradually decomposes upon exposure to light. Soluble in water, alcohol, ether, chloroform, and oils, and decomposes above this temperature. Ephedrine is isolated from stems or leaves of Ephedra, especially Ma huang (found in China and India). Medically, it is usually offered as the hydrochloride. In the treatment of bronchial asthma, ephedrine is known as a beta agonist. Compounds of this type reduce obstruction by activating the enzyme adenylate cyclase. This increases intracellular concentrations of cAMP (cyclic 3 5 -adenosine monophosphate) in bronchial smooth muscle and mast cells. Ephedrine is most useful for the treatment of mild asthma. In severe asthma, ephedrine rarely maintains completely normal airway dynamics over long periods. Ephedrine also has been used in the treatment of cerebral transient ischemic attacks, particularly with patients with vertabrobasilar artery insufficiency who have symptoms associated with relatively low blood pressure, or with postural changes in blood pressure. Ephedrine sulfate also has been used in drug therapy in connection with urticaria (hives).
2. Medicine (bronchodilator).

Definition

Different sources of media describe the Definition of 299-42-3 differently. You can refer to the following data:
1. ChEBI: A phenethylamine alkaloid that is 2-phenylethanamine substituted by a methyl group at the amino nitrogen and a methyl and a hydroxy group at position 2 and 1 respectively.
2. ephedrine: An alkaloid,C6H5CH(OH)CH(CH3)NHCH3 found inplants of the genus Ephedra, onceused as a bronchodilator in the treatmentof asthma. It is also used as astimulant and appetite suppressant.Structurally, it is a phenylethylamineand is similar to amphetamines, althoughless active. It is, however,widely used in the illegal synthesis ofmethamphetamine. The moleculehas two chiral centres. If the stereo- chemical conformations are opposite(i.e. 1R,2S or 1S,1R) the nameephedrine is used. If the conformationsare the same (1R,2R or 1S,2S)then the compound is called pseudoephedrine.

Manufacturing Process

120 grams of the fermentation product containing phenylpropanolone obtained by extraction with ether (Biochemische Zeit-schrift Vol. 115, 1921, page 282 et seq.) are allowed to run, without further purification, in for about two hours into a solution of 10 g of methylamine in 500 ml of ether in presence of 20 g of activated aluminum, for example of the type described in British Patent No.336,412, whilst stirring. Simultaneously 20-30 g of water are added, dropwise. At once the vigorous reaction begins. It is moderated by periodical cooling. Activated aluminum is aluminum, which has been amalgamated with mercury. When it contacts with water, it liberates hydrogen and an insoluble aluminum hydroxide is formed. Activated aluminum thus serves as the source of hydrogen for the reaction. When the reaction is complete the ethereal solution is filtered and the optically active base, which formed is extracted from the filtrate by means of dilute acid. There is obtained the hydrochloride of L-1-phenyl-2-methylamino-propanol-1 having a melting point of 214°C, and having the optical rotation given in the literature. The yield amounts to 25-45 g of the hydrochloride depending upon the nature of the parent material.360 g of ether extract phenylpropanolone used above as parent material are distilled under reduced pressure. 300 grams of the fraction, which distils at 100-150°C/14 mm Hg are subjected to catalytic hydrogenation in presence of colloidal platinum (70 ml of a 1% solution) and 85 grams of a 33% solution of methylamine. It is advantageous to add some ether to the reaction mixture. When absorption of hydrogen is complete, the ethereal solution is shaken with hydrochloric acid and the L-phenyl-2-methylamino-propanol-1 is isolated from the hydrochloric acid extract. The yield of the hydrochloride amounts to 110 grams. MP: 214°C.100 g of L-1-phenylpropanol-1-one-2 isolated by the method of Neuberg (Biochemische Zeitschrift Vol. 128, 1922, page 611) are dissolved in 200 ml of ether, 75 g of a solution of methylamine (33%) are added and the whole is shaken for about half an hour; condensation occurs with evolution of heat. The reaction mixture is then treated with hydrogen in presence of 70 ml of a 1% colloidal solution of platinum. The reduction product was isolated as hydrochloride. The hydrochloride of L-phenyl-2-methyl-amino-propanol-1 crystallizes from alcohol in the form of coarse prisms. MP: 214°-216°C. The free base melts at 40°C.

Therapeutic Function

Sympathomimetic; Bronchodilator

Biological Functions

Ephedrine is a naturally occurring alkaloid that can cross the blood-brain barrier and thus exert a strong CNS-stimulating effect in addition to its peripheral actions.The latter effects are primarily due to its indirect actions and depend largely on the release of norepinephrine. However, ephedrine may cause some direct receptor stimulation, particularly in its bronchodilating effects. Because it resists metabolism by both COMT and MAO, its duration of action is longer than that of norepinephrine. As is the case with all indirectly acting adrenomimetic amines, ephedrine is much less potent than norepinephrine; in addition, tachyphylaxis develops to its peripheral actions. Unlike epinephrine or norepinephrine, however, ephedrine is effective when administered orally.

Hazard

Toxic by ingestion.

Mechanism of action

Ephedrine is a naturally occurring sympathomimetic amine that possesses both direct (agonist at α- and β-receptors) and indirect activity via its potentiation of noradrenaline release from sympathetic nerve terminals. It causes an increase in HR, contractility, CO and arterial pressure (systolic > diastolic). Bronchodilation occurs via a β2-mediated mechanism, and it is occasionally used for this purpose. Its duration of action is longer than endogenous catecholamines as it is not metabolised by COMT or MAO. Tachyphylaxis can occur as a result of depletion of noradrenaline from nerve terminals and persistent occupation of adrenergic receptors. Ephedrine crosses the placenta and can increase fetal metabolic rate with a subsequent metabolic acidosis. It is usually administered by i.v. bolus at a dose of 3– 9 mg.

Pharmacology

Ephedrine increases systolic and diastolic blood pressure; heart rate is generally not increased. Contractile force of the heart and cardiac output are both increased. Ephedrine produces bronchial smooth muscle relaxation of prolonged duration when administered orally. Aside from pupillary dilation, ephedrine has little effect on the eye.

Clinical Use

Ephedrine is useful in relieving bronchoconstriction and mucosal congestion associated with bronchial asthma, asthmatic bronchitis, chronic bronchitis, and bronchial spasms. It is often used prophylactically to prevent asthmatic attacks and is used as a nasal decongestant, as a mydriatic, and in certain allergic disorders. Although its bronchodilator action is weaker than that of isoproterenol, its oral effectiveness and prolonged duration of action make it valuable in the treatment of these conditions. Because of their oral effectiveness and greater bronchiolar selectivity, terbutaline and albuterol are replacing ephedrine for bronchodilation.

Side effects

Symptoms of overdose are related primarily to cardiac and CNS effects. Tachycardia, premature systoles, insomnia, nervousness, nausea, vomiting, and emotional disturbances may develop. Ephedrine should not be used in patients with cardiac disease, hypertension, or hyperthyroidism.

Safety Profile

A human poison by an unspecified route. An experimental poison by intravenous, subcutaneous, intramuscular, and intraperitoneal routes. Moderately toxic by ingestion and parented routes. Causes rapid pulse, rise in blood pressure, and other actions similar to epinephrine. An experimental teratogen. Used in production of drugs of abuse. Has been known to cause allergic sensitization. When heated to decomposition it emits toxic fumes of NOx.

Purification Methods

Purify (-)-ephedrine by vacuum distillation (dehydrates) and forms waxy crystals or granules, and may pick up 0.5 H2O. The presence of H2O raises its melting point to 40o. [Moore & Taber J Amer Pharm Soc 24 211 1935.] The anhydrous base crystallises from dry ether [Fleming & Saunders J Chem Soc 4150 1955]. It gradually decomposes on exposure to light and is best stored in an inert atmosphere in the dark (preferably at -20o). Its solubility in H2O is 5%, in EtOH it is 1% and it is soluble in CHCl3, Et2O and mineral oils. It has pKa values in H2O of 10.25 (0o) and 8.69 (60o) [Everett & Hyne J Chem Soc 1136 1958, Prelog & H.flinger Helv Chim Acta 33 2021 1950] and pK a 8.84 in 80% aqueous methoxyethanol [Simon Helv Chim Acta 41 1835 1958]. The hydrochloride has m 220o (from EtOH/Et2O) and [] D20 -38.8o (c 2, EtOH). [IR: Chatten & Levi Anal Chem 31 1581 1959.] The anhydrous base crystallises from Et2O [Fleming & Saunders J Chem Soc 4150 1955]. [Beilstein 13 H 373, 13, III 1720, 13 IV 1879.]

Check Digit Verification of cas no

The CAS Registry Mumber 299-42-3 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 2,9 and 9 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 299-42:
(5*2)+(4*9)+(3*9)+(2*4)+(1*2)=83
83 % 10 = 3
So 299-42-3 is a valid CAS Registry Number.
InChI:InChI=1/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1

299-42-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name (-)-ephedrine

1.2 Other means of identification

Product number -
Other names L-ephedrine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:299-42-3 SDS

299-42-3Relevant articles and documents

Schmidt,Calliess

, (1912)

Schmidt

, p. 210 (1908)

BIOCATALYTICAL PROCESS FOR RACEMIZATION OF D-EPHEDRINE

-

Page/Page column 13; 14, (2020/05/28)

This invention relates to methods for racemization of dextro-rotatory ephedrine via enzymatic kinetic conversion, and is particularly useful for conversion of dextro- rotatory ephedrine (d- ephedrine) to racemic mixture of dextro-rotatory ephedrine (d-ephedrine) and levo-rotatory ephedrine (l-ephedrine) to recover the levo-rotatory ephedrine that exhibit potential bronchodilatory and anti-hypotensive activities. The process provides a suspension of Rhizopus Oryzae fungi pellets in diammonium phosphate buffer having pH in the range of pH 5 to 9 and effective sonication to extract specific enzymes for inversion of functional groups present on the chiral carbon atom of d-ephedrine molecule at low temperature which has advantages of working at lower temperature range (20 to 50 °C), lower energy consumption, lesser formation of by-products.

Evaluation of the Edman degradation product of vancomycin bonded to core-shell particles as a new HPLC chiral stationary phase

Hellinghausen, Garrett,Lopez, Diego A.,Lee, Jauh T.,Wang, Yadi,Weatherly, Choyce A.,Portillo, Abiud E.,Berthod, Alain,Armstrong, Daniel W.

, p. 1067 - 1078 (2018/08/01)

A modified macrocyclic glycopeptide-based chiral stationary phase (CSP), prepared via Edman degradation of vancomycin, was evaluated as a chiral selector for the first time. Its applicability was compared with other macrocyclic glycopeptide-based CSPs: TeicoShell and VancoShell. In addition, another modified macrocyclic glycopeptide-based CSP, NicoShell, was further examined. Initial evaluation was focused on the complementary behavior with these glycopeptides. A screening procedure was used based on previous work for the enantiomeric separation of 50 chiral compounds including amino acids, pesticides, stimulants, and a variety of pharmaceuticals. Fast and efficient chiral separations resulted by using superficially porous (core-shell) particle supports. Overall, the vancomycin Edman degradation product (EDP) resembled TeicoShell with high enantioselectivity for acidic compounds in the polar ionic mode. The simultaneous enantiomeric separation of 5 racemic profens using liquid chromatography-mass spectrometry with EDP was performed in approximately 3?minutes. Other highlights include simultaneous liquid chromatography separations of rac-amphetamine and rac-methamphetamine with VancoShell, rac-pseudoephedrine and rac-ephedrine with NicoShell, and rac-dichlorprop and rac-haloxyfop with TeicoShell.